Zydus Lifesciences Limited has announced a strategic move to strengthen its global biologics manufacturing capabilities through its wholly owned U.S. subsidiary, Zydus Pharmaceuticals USA Inc. (ZPUI). In a significant development, ZPUI has incorporated a new wholly owned subsidiary named Zylidac Bio LLC on July 11, 2025, in the United States.
Zylidac Bio LLC has been established with the immediate purpose of acquiring two biologics manufacturing facilities from Agenus West LLC and Agenus Inc., USA (collectively, “Agenus”). These facilities, located in Emeryville, California, and Berkeley, California, are referred to as the “Target Assets.” The acquisition is part of a definitive agreement signed between ZPUI and Agenus, aimed at expanding Zydus’ manufacturing footprint in the high-growth biologics segment.
The acquisition aligns with Zydus Lifesciences’ core focus in the pharmaceuticals industry, particularly in the biologics domain. By incorporating Zylidac Bio LLC and acquiring the advanced biologics facilities, Zydus aims to accelerate its innovation and production capabilities for complex biologics, including monoclonal antibodies and other advanced therapies.
Zylidac Bio LLC, like many U.S.-based Limited Liability Companies (LLCs), was incorporated without any initial share capital or cash consideration. It is fully owned by Zydus Pharmaceuticals USA Inc., thereby making it a related party under regulatory definitions.
On July 14, 2025, Zydus Lifesciences share price opened at ₹982.05, up from its previous close of ₹979.60. At 9:46 AM, the share price of Zydus Lifesciences was trading at ₹983.20, up by 0.37% on the NSE.
Also Read: Zydus Lifesciences Arm Secures Global Rights to Brazil’s Braile Biomedica’s TAVI System!
The incorporation of Zylidac Bio LLC and the acquisition of biologics facilities in the U.S. mark a significant strategic milestone for Zydus Lifesciences. This move not only enhances its global manufacturing infrastructure but also underscores the company’s commitment to expanding its presence in cutting-edge pharmaceutical segments such as biologics.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Jul 14, 2025, 9:52 AM IST
Nikitha Devi
Nikitha is a content creator with 6+ years of experience in the financial domain. Specialising in personal finance, investments, and market insights, Nikitha simplifies complex financial topics, making them accessible to readers.
Know MoreWe're Live on WhatsApp! Join our channel for market insights & updates